Experimental combo aims to boost CAR-T cell power against lymphoma
NCT ID NCT07361224
First seen Jan 23, 2026 · Last updated Apr 25, 2026 · Updated 12 times
Summary
This early-stage study tests whether adding an experimental drug called CLS-015 to standard CAR-T cell therapy can improve outcomes for people with large B-cell lymphoma that has stopped responding or is progressing. The drug aims to reverse harmful effects of immune cells called NETs, potentially helping CAR-T cells work better. The study will enroll 12 adults and focus primarily on safety.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA (LBCL) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.